MF Researcher Database

Researcher Database

Advance

Mori Yusaku

■FacultyDiabetes, Metabolism and Endocrinology
■PositionAssociate Professor
Last Updated :2025/08/08

Researcher

基本情報

Profile and Settings

  • 氏名

    Mori Yusaku

Affiliation

  • Diabetes, Metabolism and Endocrinology, Associate Professor

Location

  • East Hospital

Degree

  • Doctor of Medical Science, Showa University, Oct. 2007

Research Areas

  • Life Science, Metabolism and endocrinology

Achievements

Published Papers

  • 骨粗鬆症を有する高齢女性において血中pigment epithelium-derived factor濃度はサルコペニアの関連因子となる, 中村　彰太;永井　隆士;森　雄作;岡野　市郎;宮上　真;古賀　義法;外川内　亜美;松井　孝憲;山岸　昌一;稲垣　克記;工藤　理史;木内　祐二, 昭和医科大学雑誌, 85(3):222 - 231, Jun. 2025, Peer-reviewed, DOI:https://doi.org/10.14930/jsmu.85.3_222
  • SMTP-44D Inhibits Atherosclerotic Plaque Formation in Apolipoprotein-E Null Mice Partly by Suppressing the AGEs-RAGE Axis, Michishige Terasaki; Keita Shibata; Yusaku Mori; Tomomi Saito; Takanori Matsui; Makoto Ohara; Tomoyasu Fukui; Keiji Hasumi; Yuichiro Higashimoto; Koji Nobe; Sho-ichi Yamagishi, International Journal of Molecular Sciences, 24(7):6505 - 6505, Mar. 2023, Peer-reviewed
  • Nicotinamide Mononucleotide Prevents Free Fatty Acid-Induced Reduction in Glucose Tolerance by Decreasing Insulin Clearance., NAHLE A;JOSEPH YD;PEREIRA S;MORI Yusaku;POON F;GHADIEH HE;IVOVIC A;DESAI T;GHANEM SS;ASALLA S;MUTURI HT;JENTZ EM;JOSEPH JW;NAJJAR SM;GIACCA A, Int J Mol Sci, 22(24):13224, Dec. 2021, Peer-reviewed, DOI:10.3390/ijms222413224
  • Glucose-Dependent Insulinotropic Polypeptide Suppresses Foam Cell Formation of Macrophages through Inhibition of the Cyclin-Dependent Kinase 5-CD36 Pathway., TERASAKI Michishige;YASHIMA Hironori;MORI Yusaku;SAITO Tomomi;SHIRAGA Yoshie;KAWAKAMI Raichi;OHARA Makoto;FUKUI Tomoyasu;HIRANO Tsutomu;YAMADA Yuichiro;SEINO Yutaka;YAMAGISHI Sho-ichi, Biomedicines, 9(7):832, Jul. 2021, Peer-reviewed
  • Roles of vascular endothelial and smooth muscle cells in the vasculoprotective effect of insulin in a mouse model of restenosis., MORI Yusaku;GONZALEZ MEDINA M;LIU Z;GUO J;DINGWELL LS;CHIANG S;KAHN CR;HUSAIN M;GIACCA A, Diab Vasc Dis Res, 18(3):1.47916E+16, May 2021, Peer-reviewed
  • Very rare case of Graves' disease with resistance to methimazole: a case report and literature review., MORI Yusaku;HIROMURA Munenori;TERASAKI Michishige;KUSHIMA Hideki;OHARA Makoto;FUKUI Tomoyasu;TAKAHASHI Yasuyoshi;Yamagishi Sho-Ichi, J Int Med Res, 49(3):3.00061E+14, Mar. 2021, Peer-reviewed
  • AGE-RAGE Axis Stimulates Oxidized LDL Uptake into Macrophages through Cyclin-Dependent Kinase 5-CD36 Pathway via Oxidative Stress Generation, YASHIMA Hironori;TERASAKI Michishige;SOTOKAWAUCHI Ami;MATSUI Takanori;MORI Yusaku;SAITO Tomomi;OSAKA Naoya;KUSHIMA Hideki;HIROMURA Munenori;OHARA Makoto;FUKUI Tomoyasu;YAMAGISHI Sho-ichi, Int J Mol Sci, 21(23):9263, Dec. 2020, Peer-reviewed
  • Resveratrol Inhibits Neointimal Growth after Arterial Injury in High-Fat-Fed Rodents: The Roles of SIRT1 and AMPK., GUO J;PEREIRA TJ;MORI Yusaku;GONZALEZ Medina M;BREEN DM;DALVI PS;ZHANG H;McCole DF;MCBURNEY MW;HEXIMER SP;TSIANI EL;DOLINSKY VW;GIACCA A, J Vasc Res, 57(6):325 - 340, Aug. 2020, Peer-reviewed
  • Association of Hemoglobin A1c, 1,5-Anhydro-D-Glucitol and Glycated Albumin with Oxidative Stress in Type 2 Diabetes Mellitus Patients: A Cross-Sectional Study., KOHATA Yo;OHARA Makoto;NAGAIKE Hiroe;FUJIKAWA Tomoki;OSAKA Naoya;GOTO Satoshi;FUKASE Ayako;KUSHIMA Hideki;HIROMURA Munenori;TERASAKI Michishige;MORI Yusaku;FUKUI Tomoyasu;OUCHI Motoshi;SUZUKI Tatsuya;HIRANO Tsutomu;YAMAGISHI Sho-Ichi, Diabetes Ther, 11(3):655 - 665, Mar. 2020, Peer-reviewed
  • Pancreatic fat accumulation evaluated by multi-detector computed tomography in patients with type 2 diabetes., Ayako Fukase; Tomoyasu Fukui; Hiroto Sasamori; Munenori Hiromura; Michishige Terasaki; Yusaku Mori; Toshiyuki Hayashi; Takeshi Yamamoto; Makoto Ohara; Satoshi Goto; Hiroe Nagaike; Tsutomu Hirano; Sho-Ichi Yamagishi, Journal of diabetes investigation, 11(5):1188 - 1196, Mar. 2020
  • GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease-A Systematic Review., MORI Yusaku;MATSUI T;HIRANO Tsutomu;YAMAGISHI Sho-ichi, Int J Mol Sci, 21(4):1509, Feb. 2020, Peer-reviewed
  • β-Endorphin Mediates the Development and Instability of Atherosclerotic Plaques., Taisuke Okano; Kengo Sato; Remina Shirai; Tomomi Seki; Koichiro Shibata; Tomoyuki Yamashita; Ayaka Koide; Hitomi Tezuka; Yusaku Mori; Tsutomu Hirano; Takuya Watanabe, International journal of endocrinology, 2020:4139093 - 4139093, 2020
  • Circulating anti-glutamic acid decarboxylase-65 antibody titers are positively associated with the capacity of insulin secretion in acute-onset type 1 diabetes with short duration in a Japanese population., So Yamamura; Tomoyasu Fukui; Yusaku Mori; Toshiyuki Hayashi; Takeshi Yamamoto; Makoto Ohara; Ayako Fukase; Hiroto Sasamori; Tetsuro Kobayashi; Tsutomu Hirano, Journal of diabetes investigation, 10(6):1480 - 1489, Nov. 2019
  • Luseogliflozin attenuates neointimal hyperplasia after wire injury in high-fat diet-fed mice via inhibition of perivascular adipose tissue remodeling., MORI Yusaku;TERASAKI Michishige;HIROMURA Munenori;SAITO Tomomi;KUSHIMA Hideki;KOSHIBU Masakazu;OSAKA Naoya;OHARA Makoto;FUKUI Tomoyasu;OHTAKI Hirokazu;HIRANO Tsutomu;YAMAGISHI Sho-Ichi, Cardiovasc Diabetol, 18(1):143, Oct. 2019, Peer-reviewed
  • Chemerin-9, a potent agonist of chemerin receptor (ChemR23), prevents atherogenesis., SATO Kengo;YOSHIZAWA Hayami;SEKI Tomomi;SHIRAI Remina;YAMASHITA Tomoyuki;OKANO Taisuke;SHIBATA Koichiro;WAKAMATSU Miyu J;MORI Yusaku;MORITA Toshisuke;MATSUYAMA Taka-aki;ISHIBASHI-UEDA Hatsue;HIRANO Tsutomu;WATANABE Takuya, Clin Sci (Lond), 133(16):1779 - 1796, Aug. 2019, Peer-reviewed
  • Involvement of Vascular Endothelial Cells in the Anti-atherogenic Effects of Liraglutide in Diabetic Apolipoprotein E-null Mice, KOSHIBU Masakazu;MORI Yusaku;KUSHIMA Hideki;HIROMURA Munenori;KOHASHI Kyoko;TERASAKI Michishige;OSAKA Naoya;FUJIKAWA Tomoki;FUKUI Tomoyasu;HIRANO Tsutomu, Showa Univ J Med Sci, 31(2):115 - 124, Jun. 2019, Peer-reviewed
  • Antiatherogenic effects of liraglutide in hyperglycemic apolipoprotein E-null mice via AMP-activated protein kinase-independent mechanisms, KOSHIBU Masakazu;MORI Yusaku;SAITO Tomomi;KUSHIMA Hideki;HIROMURA Munenori;TERASAKI Michishige;TAKADA Michiya;FUKUI Tomoyasu;HIRANO Tsutomu, Am J Physiol Endocrinol Metab, 316(5):E895 - E907, May 2019, Peer-reviewed
  • Legumain Promotes Atherosclerotic Vascular Remodeling, OZAWA Nana;SATO Yuki;MORI Yukari;MASUDA Hiroko;YAMANE Mao;YAMAMOTO Yuka;SHIRAI Remina;WATANABE Rena;SATO Kengo;MORI Yusaku;HIRANO Tsutomu;WATANABE Takuya, Int J Mol Sci, 20(9):2195, May 2019, Peer-reviewed
  • Pheochromocytoma presenting with severe hyperglycemia and metabolic acidosis following intra-articular glucocorticoid administration: a case report., TOMOYASU Masako;MORI Yusaku;FUKASE Ayako;KUSHIMA Hideki;HIRANO Tsutomu, J Med Case Rep, 13(1):3, Jan. 2019, Peer-reviewed
  • Inhibitory effects of vasostatin-1 against atherogenesis, SATO Yuki;WATANABE Rena;UCHIYAMA Nozomi;OZAWA Nana;TAKAHASHI Yui;SHIRAI Remina;SATO Kengo;MORI Yusaku;MATSUYAMA Taka-aki;ISHIBASHI-UEDA Hatsue;HIRANO Tsutomu;WATANABE Takuya, Clin Sci (Lond), 132(23):2493 - 2507, Dec. 2018, Peer-reviewed
  • A Dipeptidyl Peptidase-4 Inhibitor Suppresses Macrophage Foam Cell Formation in Diabetic db/db Mice and Type 2 Diabetes Patients., TERASAKI Michishige;HIROMURA Munenori;MORI Yusaku;KOHASHI Kyoko;KUSHIMA Hideki;KOSHIBU Masakazu;SAITO Tomomi;YASHIMA Hironori;WATANABE Takuya;HIRANO Tsutomu, Int J Endocrinol, 2018:8458304, Dec. 2018, Peer-reviewed
  • Glucose-Dependent Insulinotropic Polypeptide Suppresses Peripheral Arterial Remodeling in Male Mice, MORI Yusaku;KUSHIMA Hideki;KOSHIBU Masakazu;SAITO Tomomi;HIROMURA Munenori;KOHASHI Kyoko;TERASAKI Michishige;SEINO Yutaka;YAMADA Yuichiro;HIRANO Tsutomu, Endocrinology, 159(7):2717 - 2732, Jul. 2018, Peer-reviewed
  • Anti-Atherogenic Effects of Vaspin on Human Aortic Smooth Muscle Cell/Macrophage Responses and Hyperlipidemic Mouse Plaque Phenotype, SATO Kengo;SHIRAI Remina;YAMAGUCHI Maho;YAMASHITA Tomoyuki;SHIBATA Koichiro;OKANO Taisuke;MORI Yusaku;MATSUYAMA Taka-aki;ISHIBASHI-UEDA Hatsue;HIRANO Tsutomu;WATANABE Takuya, Int J Mol Sci, 19(6):E1732, Jun. 2018, Peer-reviewed
  • Effects of insulin and analogues on carcinogen-induced mammary tumours in high-fat-fed rats., Mori Yusaku;Ko Eunhyoung;Furrer Rudolf;Qu Linda C;Wiber Stuart C;Fantus I George;Thevis Mario;Medline Alan;Giacca Adria, Endocrine connections, 7(5):739 - 748, Apr. 2018, Peer-reviewed
  • Adropin Contributes to Anti-Atherosclerosis by Suppressing Monocyte-Endothelial Cell Adhesion and Smooth Muscle Cell Proliferation, SATO Kengo;YAMASHITA Tomoyuki;SHIRAI Remina;SHIBATA Koichiro;OKANO Taisuke;YAMAGUCHI Maho;MORI Yusaku;HIRANO Tsutomu;WATANABE Takuya, Int J Mol Sci, 19(5):E1293, Apr. 2018, Peer-reviewed
  • Catestatin Prevents Macrophage-Driven Atherosclerosis but Not Arterial Injury-Induced Neointimal Hyperplasia, KOJIMA Miho;OZAWA Nana;MORI Yusaku;TAKAHASHI Yui;WATANABR-KOMINATO Kaho ;SHIRAI Remina;WATANABE Rena;SATO Kengo;MATSUYAMA Taka-aki;ISHIBASHI-UEDA Hatsue;KOBA Shinji;KOBAYASHI Youichi;HIRANO Tsutomu;WATANABE Takuya, Thromb Haemost, 118(1):182 - 194, Jan. 2018, Peer-reviewed
  • IKKβ inhibition prevents fat-induced beta cell dysfunction in vitro and in vivo in rodents, IVOVIC Aleksandar;OPRESCU Andrei I;KOULAJIAN Khajag;MORI Yusaku;EVERSLEY Judith A;ZHANG Liling;NINO-FONG Rodolfo;LEWIS Gary F;DONATH Marc Y;KARIN Michael;WHEELER Michael B;EHSES Jan;VOLCHUK Allen;CHAN Catherine B;GIACCA Adria, Diabetologia, 60(10):2021 - 2032, Oct. 2017, Peer-reviewed
  • Increased blood pressure in nesfatin/nuclebindin-2-transgenic mice, MORI Yusaku;SHIMIZU Hiroyuki;KUSHIMA Hideki;HIROMURA Munenori;TERASAKI Michishige;TANAKA Michitaka;OSAKI Aya;HIRANO Tsutomu, Hypertens Res, 40(10):861 - 867, Oct. 2017, Peer-reviewed
  • The role of endothelial nitric oxide in the anti-restenotic effects of liraglutide in a mouse model of restenosis, KUSHIMA Hideki;MORI Yusaku;KOSHIBU Masakazu;HIROMURA Munenori;KOHASHI Kyoko;TERASAKI Michishige;FUKUI Tomoyasu;HIRANO Tsutomu, Cardiovasc Diabetol, 16(1):122, Oct. 2017, Peer-reviewed
  • Combination Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor and a Dipeptidyl Peptidase-4 Inhibitor Additively Suppresses Macrophage Foam Cell Formation and Atherosclerosis in Diabetic Mice, Michishige Terasaki; Munenori Hiromura; Yusaku Mori; Kyoko Kohashi; Hideki Kushima; Makoto Ohara; Takuya Watanabe; Olov Andersson; Tsutomu Hirano, INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2017:1365209, 2017
  • Suppressive Effects of Glucose-Dependent Insulinotropic Polypeptide on Cardiac Hypertrophy and Fibrosis in Angiotensin II-Infused Mouse Models., HIROMURA Munenori;MORI Yusaku;KOHASHI Kyoko;TERASAKI Michishige;SHINMURA Kyoko;NEGORO Takaharu;KAWASHIMA Hikaru;KOGURE Mao;WACHI Toshimi;WATANABE Rena;SATO Kengo;KUSHIMA Hideki;TOMOYASU Masako;NAKANO Yasuko;YAMADA Yuichiro;WATANABE Takuya;HIRANO Tsutomu, Circ J, 80(9):1988 - 1997, Aug. 2016, Peer-reviewed
  • Insulin decreases atherosclerotic plaque burden and increases plaque stability via nitric oxide synthase in apolipoprotein E-null mice, Yusaku Mori; Simon Chiang; Michelle P. Bendeck; Adria Giacca, AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 311(2):E335 - E345, Aug. 2016
  • Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits., HIRANO Tsutomu;YAMASHITA Satoko;TAKAHASHI Masaki;HASHIMOTO Hiroyuki;MORI Yusaku;GOTO Moritaka, Metabolism, 65(6):893 - 903, Jun. 2016, Peer-reviewed
  • Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals., HIRANO Tsutomu;MORI Yusaku, J Diabetes Investig, 7(Suppl.1):80 - 86, Apr. 2016, Peer-reviewed
  • Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice., TERASAKI Michishige;HIROMURA Munenori;MORI Yusaku;KOHASHI Kyoko;NAGASHIMA Masaharu;KUSHIMA Hideki;WATANABE Takuya;HIRANO Tsutomu, PloS One, 10(11):e0143396, Nov. 2015, Peer-reviewed
  • The effect of insulin to decrease neointimal growth after arterial injury is endothelial nitric oxide synthase-dependent, GUO June;BREEN Danna M;PEREIRA Troy J;DALVI Prasad S;ZHANG Hangjun;MORI Yusaku;GHANIM Husam;TUMIATI Laura;FANTUS I George;BENDECK Michelle P;DANDONA Paresh;RAO Vivek;DOLINSKY Vernon W;HEXIMER Scott P;GIACCA Adria, Atherosclerosis, 241(1):111 - 120, Jul. 2015, Peer-reviewed
  • FFA-induced hepatic insulin resistance in vivo is mediated by PKCδ, NADPH oxidase, and oxidative stress, PEREIRA Sandra;PARK Edward;MORI Yusaku;HABER C Andrew;HAN Ping;UCHIDA Toyoyoshi;STAVAR Laura;OPRESCU Andrei I;KOULAJIAN Khajag;IVOVIC Alexander;YU Zhiwen;LI Deling ;BOWMAN Thomas A;DEWALD Jay;EL-BENNA Jamel;BRINDLEY David N;GUTIERREZ-JUAREZ Roger;LAM Tony K T;NAJJAR Sonia M;MCKAY Robert A;GIACCA Adria;FANTUS I George, Am J Physiol Endocrinol Metab, 307(1):E34 - E46, Jul. 2014, Peer-reviewed
  • Local insulin application on the carotid artery inhibits neointima formation, CHIANG Simon ;BREEN Danna M;GUO June ;MORI Yusaku;GIACCA Adria, Can J Physiol Pharmacol, 91(12):1086 - 1094, Dec. 2013, Peer-reviewed
  • Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice, Michishige Terasaki; Masaharu Nagashima; Takuya Watanabe; Kyoko Nohtomi; Yusaku Mori; Akira Miyazaki; Tsutomu Hirano, METABOLISM-CLINICAL AND EXPERIMENTAL, 61(7):974 - 977, Jul. 2012
  • Ezetimibe alone or in combination with pitavastatin prevents kidney dysfunction in 5/6 nephrectomized rats fed high-cholesterol, Yusaku Mori; Tsutomu Hirano, METABOLISM-CLINICAL AND EXPERIMENTAL, 61(3):379 - 388, Mar. 2012
  • Apolipoprotein B48 Increment After Test Meal A Increases Small Dense Low-Density　Lipoprotein Cholesterol Independently of Triglyceride, 森　雄作;山本　剛史;徳野　杏奈;平野　勉, 糖尿病, 53(8):593 - 600, Aug. 2010, Peer-reviewed
  • Remnant lipoprotein cholesterol homogenous assay (RemL-C) is closely associated with very-low-density lipoprotein remnants: comparison with the immunoseparation assay., Nagashima M; Mori Y; Morita R; Takada M; Lee S; Taira T; Miyauchi K; Kuwata H; Kayahara N; Hirano T, Rinsho byori. The Japanese journal of clinical pathology, 56(11):973 - 979, Nov. 2008
  • Significant increase of apolipoprotein b48 levels by a standard test meal in type 2 diabetic patients with nephropathy, Takeshi Yamamoto; Tsutomu Hirano; Yusaku Mori; Anna Tokuno; Masaharu Nagashima; Michiya Takada; Ryo Morita; Soushou Lee; Toshiyuki Hayashi; Mitsuru Adachi, JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 15(4):199 - 205, Aug. 2008
  • Remarkable increase of apolipoprotein B48 level in diabetic patients with end-stage renal disease, Toshiyuki Hayashi; Tsutornu Hirano; Takayasu Taira; Anna Tokuno; Yusaku Mori; Shinji Koba; Mitsuru Adachi, ATHEROSCLEROSIS, 197(1):154 - 158, Mar. 2008
  • Decreased peroxisome proliferator-activated receptor a gene expression is associated with dyslipidemia in a rat model of chronic renal failure, Yusaku Mori; Tsutomu Hirano; Masaharu Nagashima; Yuji Shiraishi; Tomoyasu Fukui; Mitsuru Adachi, METABOLISM-CLINICAL AND EXPERIMENTAL, 56(12):1714 - 1718, Dec. 2007
  • The effects of statin and fibrate on lowering small dense LDL-cholesterol in hyperlipidemic patients with type 2 diabetes, Anna Tokuno; Tsutomu Hirano; Toshiyuki Hayashi; Yusaku Mori; Takeshi Yamamoto; Masaharu Nagashima; Yuji Shiraishi; Yasuki Ito; Mitsuru Adachi, JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 14(3):128 - 132, Jun. 2007

Presentations

  • Glucose-dependent insulinotropic polypeptideの心筋細胞への作用－糖尿病性心筋症の新たな治療標的－, 森　雄作;寺崎　道重;広村　宗範;小原　信;福井　智康;山岸　昌一, 脳心血管抗加齢研究会第17回学術大会, 17 Dec. 2021, 大阪・Web開催
  • Glucose-dependent insulinotropic polypeptideの心リモデリング抑制作用：2型糖尿病モデルマウスにおける検討, 森　雄作;小原　信;山岸　昌一, 第21回日本抗加齢医学会総会, 25 Jun. 2021, 京都・WEB開催
  • 終末糖化産物受容体(RAGE)阻害アプタマーはApoE欠損マウスの動脈硬化進展を抑制する, 寺﨑　道重;森　雄作;八島　広典;外川内　亜美;松井　孝憲;斎藤　智美;九島　秀樹;広村　宗範;大坂　直也;小原　信;福井　智康;山岸　昌一, 第64回日本糖尿病学会年次学術集会, 20 May 2021, Web開催
  • GIPの心保護作用：肥満2型糖尿病モデルマウスでの検討, 森　雄作;広村　宗範;寺崎　道重;九島　秀樹;斎藤　智美;大阪　直也;八島　広典;小原　信;福井　智康;山岸　昌一, 第94回日本内分泌学会学術総会, 22 Apr. 2021, バーチャル開催
  • グルカゴンの抗動脈硬化作用：動脈硬化モデルマウスにおける検討, 森　雄作;九島　秀樹;寺﨑　道重;広村　宗範;斎藤　智美;小渋　正和;大坂　直也;八島　広典;小原　信;福井　智康;平野　勉;山岸　昌一, 第63回日本糖尿病学会年次学術集会, 09 Oct. 2020, Web開催
  • GIP（Glucose-dependent insulinotropic polypeptide）はマウスとヒトのマクロファージ泡沫化を抑制する, 八島　広典;寺﨑　道重;齋藤　智美;森　雄作;広村　宗範;九島　秀樹;小澁　正和;大坂　直也;小原　信;福井　智康;山田　祐一郎;清野　裕;平野　勉;山岸　昌一, 第63回日本糖尿病学会年次学術集会, 05 Oct. 2020, Web開催
  • Teneligliptinは1型糖尿病マウスと1型糖尿病患者のマクロファージ泡沫化をAGEs系の抑制により改善する, 寺﨑　道重;八島　広典;森　雄作;斎藤　智美;広村　宗範;九島　秀樹;小澁　正和;大坂　直也;小原　信;福井　智康;平野　勉;山岸　昌一, 第63回日本糖尿病学会年次学術集会, 05 Oct. 2020, Web開催
  • A dipeptidyl peptidase-4 (DPP-4) inhibitor suppresses foam cell formation of macrophages through the suppression of CD36 in type 1 diabetes., TERASAKI Michishige;YASHIMA Hironori;MORI Yusaku;SAITO Tomomi;HIROMURA Munenori;KUSHIMA Hideki;KOSHIBU Masakazu;OSAKA Naoya;OHARA Makoto;FUKUI Tomoyasu;HIRANO Tsutomu;YAMAGISHI Sho-ichi, 56th Annual Meeting of the European Association for the Study of Diabetes, 24 Sep. 2020, VIRTUAL
  • Glucose-dependent insulinotropic polypeptide (GIP) inhibits macrophages foam cell formation via suppression of CD36 expression, YASHIMA Hironori;TERASAKI Michishige;SAITO Tomomi;MORI Yusaku;HIROMURA Munenori;KUSHIMA Hideki;KOSHIBU Masakazu;OSAKA Naoya;OHARA Makoto;FUKUI Tomoyasu;SEINO Yutaka;YAMADA Yuichiro;HIRANO Tsutomu;YAMAGISHI Sho-ichi, 56th EASD Annual Meeting, 24 Sep. 2020, VIRTUAL Congress
  • 2型糖尿病におけるHbA1c、GA及び1,5-AGと酸化ストレスの関連の検討, 九島　秀樹;小原　信;藤川　大輝;後藤　聡;深瀬　絢子;長池　弘江;佐藤　展子;広村　宗範;髙畑　洋;寺﨑　道重;福井　智康;森　雄作;山岸　昌一, 第34回日本糖尿病合併症学会, 28 Sep. 2019, 大阪
  • Glucose-dependent insulinotropic peptide remarkably suppresses macrophage foam cell formation in the mice and the humans., YASHIMA Hironori;TERASAKI Michishige;SAITO Tomomi ;MORI Yusaku;HIROMURA Munenori;KUSHIMA Hideki;KOSHIBU Masakazu;OHARA Makoto;FUKUI Tomoyasu;SEINO Yutaka;YAMADA Yuichiro;HIRANO Tsutomu, 55th Annual Meeting of the European Association for the Study of Diabetes, 19 Sep. 2019, Barcelona
  • インクレチン関連薬の抗動脈硬化作用, 平野　勉;森　雄作, 第51回日本動脈硬化学会総会・学術集会, 12 Jul. 2019, 京都
  • 動脈障害マウスモデルにおいてルセオグリフロジンは血糖低下作用と独立した動脈狭窄抑制作用を示す, 森　雄作;寺崎　道重;斎藤　智美;広村　宗範;九島　秀樹;小澁　正和;義間　大也;八島　広典;平野　勉, 第51回日本動脈硬化学会総会・学術集会, 12 Jul. 2019, 京都
  • Vasoprotective effect of GLP-1 receptor agonists in experimental animals, 森　雄作;平野　勉, 第62回日本糖尿病学会年次学術集会, 25 May 2019, 仙台
  • ルセオグリフロジンの血糖低下作用と独立した動脈保護作用 : マウスモデルにおけるインスリンとの比較検討, 森　雄作;九島　秀樹;広村　宗範;寺﨑　道重;斎藤　智美;小澁　正和;八島　広典;平野　勉, 第62回日本糖尿病学会年次学術集会, 24 May 2019, 仙台
  • 妊娠糖尿病におけるインスリン療法の導入率：自己血糖測定の保険適応に該当する患者としない患者での解析, 小橋　京子;森　雄作;長村　杏奈;義間　大也;金古　政隆;平野　勉, 第62回日本糖尿病学会年次学術集会, 24 May 2019, 仙台
  • Teneligliptinは1型糖尿病マウスと1型糖尿病患者のマクロファージ泡沫化をex vivoで抑制する, 八島　広典;寺﨑　道重;広村　宗範;小橋　京子;齋藤　智美;森　雄作;九島　秀樹;小澁　正和;藤川　大輝;大坂　直也;平野　勉, 第62回日本糖尿病学会年次学術集会, 23 May 2019, 仙台
  • Glucose-dependent insulinotropic polypeptide suppresses arterial remodelling in mice: role of a calcium-mediated signalling pathway in vascular endothelial cells., MORI Yusaku;KUSHIMA Hideki;KOSHIBU Masakazu;SAITO Tomomi;HIROMURA Munenori;KOHASHI Kyoko;TERASAKI Michishige;HIRANO Tsutomu, 54th annual meeting of the European Association for the Study of Diabetes, 02 Oct. 2018, Berlin
  • Vasoprotective effects of Vildagliptin in mice is masked by Metformin - overlapping mechanisms implied, KUSHIMA Hideki;MORI Yusaku;KOSHIBU Masakazu;HIROMURA Munenori;KOHASHI Kyoko;TERASAKI Michishige;HIRANO Tsutomu, 78th Scientific Sessions American Diabetes Association, 25 Jun. 2018, Orlando
  • Liraglutide Suppresses Atherosclerosis via AMP-Activated Protein Kinase Dependent and Independent Mechanisms in Diabetic Apolipoprotein Enull Mice, KOSHIBU Masakazu;MORI Yusaku;KUSHIMA Hideki;HIROMURA Munenori;KOHASHI Kyoko;TERASAKI Michishige;HIRANO Tsutomu, American Diabetes Association 78th Scientific Sessions, 25 Jun. 2018, Orlando
  • Anorexic Peptide Nesfatin-1 Exerts Vasoprotective Effects in Injured Arteries of Mice, MORI Yusaku;SHIMIZU Hiroyuki;KUSHIMA Hideki;TERASAKI Michishige;HIROMURA Munenori;KOSHIBU Masakazu;KOHASHI Kyoko;HIRANO Tsutomu, 78th Scientific Sessions American Diabetes Association, 24 Jun. 2018, Orlando
  • かかりつけ医での特定健康診査受診者と健診対象者全体との相違点についての検討, 義間　大也;長嶋　理晴;森　雄作;平野　勉, 第61回日本糖尿病学会年次学術集会, 26 May 2018, 東京
  • 日本人1型糖尿病の膵体積と各種背景因子との関係, 深瀬　絢子;福井　智康;笹森　寛人;山村　聡;林　俊行;長村　杏奈;森　雄作;山本　剛史;高田　道哉;小原　信;坂下　暁子;新村　京子;小橋　京子;広村　宗範;九島　秀樹;山本　咲;長池　弘江;後藤　聡;高畑　洋;平野　勉, 第61回日本糖尿病学会年次学術集会, 26 May 2018, 東京
  • 摂食抑制ペプチドのネスファチン-1の動脈保護作用―マウスモデルを用いた検討, 森　雄作;清水　弘行;九島　秀樹;寺﨑　道重;広村　宗範;小橋　京子;小澁　正和;平野　勉, 第61回日本糖尿病学会年次学術集会, 25 May 2018, 東京
  • 非妊娠時のインスリン分泌とインスリン抵抗性の指標を用いてインスリンが必要となる妊娠糖尿病患者を予測できるか, 小橋　京子;森　雄作;長村　杏奈;友安　雅子;田邉　優希;平野　勉, 第61回日本糖尿病学会年次学術集会, 25 May 2018, 東京
  • エンパグリフロジン（EMPA）12か月間内服による腎機能の改善効果について, 清水　弘行;森　雄作;平野　勉, 第61回日本糖尿病学会年次学術集会, 25 May 2018, 東京
  • 世界糖尿病デーイベントでの筋力指標測定と骨折リスクに関するアンケート調査　糖代謝異常による骨折リスクと身体活動量の評価, 吉川　雅之;葛城　怜子;飯野　里佳;諸戸　安惠;中田　美江;八島　広典;小渋　正和;後藤　聡;長池　弘江;深瀬　絢子;山村　聡;佐藤　展子;山本　咲;九島　秀樹;広村　宗範;小橋　京子;新村　京子;小原　信;山本　剛史;森　雄作;長村　杏奈;林　俊行;高橋　育克;福井　智康;佐々木　忠徳;平野　勉, 第61回日本糖尿病学会年次学術集会, 24 May 2018, 東京
  • 2型糖尿病患者における1,5-AGと酸化ストレスの関連の検討, 九島　秀樹;小原　信;藤川　大輝;八島　広典;大坂　直也;義間　大也;小澁　正和;後藤　聡;佐藤　展子;田邉　優希;広村　宗範;新村　京子;小橋　京子;森　雄作;髙橋　育克;山本　剛史;林　俊行;福井　智康;平野　勉, 第32回日本糖尿病合併症学会, 27 Oct. 2017, 東京
  • Anti-atherogenic effects of liraglutide independent of the AMPK pathway in diabetic apolipoprotein E-null mice, KOSHIBU Masakazu;MORI Yusaku;KUSHIMA Hideki;KOHASHI Kyoko;HIROMURA Munenori;TERASAKI Michishige;FUKUI Tomoyasu;HIRANO Tsutomu, 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2017, 14 Sep. 2017, Lisbon
  • Vascular Protective Effect of Glucose-dependent Insulinotropic Polypeptide via the Endothelial PKA/AMPK/eNOS Pathway, 森　雄作;九島　秀樹;小澁　正和;広村　宗範;小橋　京子;寺崎　道重;福井　智康;平野　勉, 53rd annual meeting of the European Association for the Study of Diabetes, 13 Sep. 2017, Lisbon
  • Protective Effect of Liraglutide against Vascular Restenosis via Enhancement of Endothelial Nitric Oxide Production, KUSHIMA Hideki;MORI Yusaku;HIROMURA Munenori;KOHASHI Kyoko;KOSHIBU Masakazu;TERASAKI Michishige;FUKUI Tomoyasu;HIRANO Tsutomu, American Diabetes Association 77th Scientific Sessions, 11 Jun. 2017, San Diego
  • GIPは血管内皮細胞のPKA・AMPK・NOを介して動脈リモデリングを抑制する, 森　雄作;九島　秀樹;広村　宗範;小橋　京子;寺﨑　道重;小澁　正和;平野　勉, 第60回日本糖尿病学会年次学術集会, 19 May 2017, 名古屋
  • 75gブドウ糖負荷試験の血糖値を用いたインスリン療法が必要となる妊娠糖尿病患者のスクリーニングの試み, 小橋　京子;森　雄作;田邉　優希;友安　雅子;長村　杏奈;平野　勉, 第60回日本糖尿病学会年次学術集会, 19 May 2017, 名古屋
  • Cardiovascular protective effects of glucose-dependent insulinotropic polypeptide in preclinical models, 森　雄作;平野　勉, 第60回日本糖尿病学会年次学術集会, 19 May 2017, 名古屋
  • マウス動脈傷害モデルにおけるliraglutideのnitric oxideを介した動脈リモデリング抑制効果, 九島　秀樹;森　雄作;山本　剛史;小原　信;新村　京子;小橋　京子;広村　宗範;田邉　優希;小澁　正和;後藤　聡;平野　勉, 第60回日本糖尿病学会年次学術集会, 18 May 2017, 名古屋
  • Glucose-dependent insulinotropic polypeptide suppresses neointimal hyperplasia after arterial injury in an experimental model, KUSHIMA Hideki;MORI Yusaku;TOMOYASU Masako;KOHASHI Kyoko;HIROMURA Munenori;TERASAKI Michishige;HIRANO Tsutomu, American Diabetes Association 76th Scientific Sessions, 13 Jun. 2016, New Orleans
  • Glargine and Detemir do not Increase Tumour Incidence or Multiplicity Compared with Unmodified Insulin in a Carcinogen-Induced Rat Model of Breast Cancer, MORI Yusaku;KO Eunhyoung;WIBER Stuart C;FANTUS George I ;MEDLINE Alan;GIACCA Adria, American Diabetes Association 76th Scientific Sessions, 12 Jun. 2016, New Orleans
  • The Roles of NOD Receptors in Fat-induced Beta-Cell Dysfunction, IVOVIC Alexander;DESAI Tejas;KOULAJIAN Khajag;YE Kaitai;MORI Yusaku;GIACCA Adria, 76th Scientific Sessions American Diabetes Association, 10 Jun. 2016, New Orleans
  • Sensor augmented pump (SAP) システムを導入した１型糖尿病患者における高血糖、低血糖、血糖変動に関する検討, 山本　剛史;小原　信;森　雄作;山本　咲;林　俊行;福井　智康;平野　勉, 第59回日本糖尿病学会年次学術集会, 21 May 2016, 京都
  • 動脈障害後狭窄モデルでのglucose-dependent insulinotropic peptideの血管保護効果, 九島　秀樹;森　雄作;広村　宗範;小橋　京子;新村　京子;友安　雅子;寺﨑　道重;平野　勉, 第59回日本糖尿病学会年次学術集会, 21 May 2016, 京都
  • Dipeptidyl peptidase-4 inhibitor suppresses inflammation in U937 monocytes by inhibiting phosphorylation of caveolin-1 through CD26, HIROMURA Munenori;NOHTOMI Kyoko;TERASAKI Michishige;MORI Yusaku;KUWATA Hirotaka;HIRANO Tsutomu, 51st European Association for the Study of Diabetes(EASD) Annual Meeting, 15 Sep. 2015, Stockholm
  • Amelioration of hyperglycaemia with SGLT2i prevents atherosclerosis through suppression of macrophage form cell formation in diabetic mice independent of insulin action, TERASAKI Michishige;HIROMURA Munenori;KOHASHI Kyoko;KUSHIMA Hideki;NAGASHIMA Masaharu;MORI Yusaku;HIRANO Tsutomu, 51th Annual Meeting of the European Association for the Study of Diabetes, 15 Sep. 2015, Stockholm
  • Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals, HIRANO Tsutomu;MORI Yusaku, Incretin 2015, 30 Jul. 2015, Vancouver
  • SGLT‐2阻害薬(Ipragliflozin)はdb/dbマウスの腹腔マクロファージ泡沫化を抑制する, 寺﨑　道重;広村　宗範;小橋　京子;九島　秀樹;長嶋　理晴;森　雄作;平野　勉, 第47回日本動脈硬化学会総会・学術集会, 10 Jul. 2015, 仙台
  • A Sodium glucose cotransporter-2 inhibitor prevents the progression of macrophage-driven atherosclerosis dependent on glycaemic control in diabetic apolipoprotein E-Null mice., TERASAKI Michishige;HIROMURA Munenori;KOHASHI Kyoko;KUSHIMA Hideki;NAGASHIMA Masaharu;MORI Yusaku;HIRANO Tsutomu, 75th Scientific Sessions American Diabetes Association, 08 Jun. 2015, Boston
  • A DPP-4 inhibitor but not incretins suppresses the progression of abdominal aorta aneurysms in angiotensin II- infused apolipoprotein-E null mice　, KOHASHI Kyoko;HIROMURA Munenori;MORI Yusaku;TERASAKI Michishige;WATANABE Takuya;KUSHIMA Hideki;SHINMURA Kyoko;TOMOYASU Masako;NAGASHIMA Masaharu;HIRANO Tsutomu, 75th Scientific Sessions American Diabetes Association, 08 Jun. 2015, Boston
  • Insulin decreases atherosclerotic plaque burden and increases plaque stability via nitric oxide synthase　in Apolipoprotein E null mice, MORI Yusaku;CHIANG Simon;BENDECK Michelle P;HEXIMER Scott P;GIACCA Adria, 75th Scientific Sessions American Diabetes Association, 08 Jun. 2015, Boston
  • Preventive Effects of Dipeptidyl Peptidase-4 Inhibitor on Angiotensin Ⅱ-induced Cardiac Hypertrophy Independent of Incretin Signaling in ApoE null mice., HIROMURA Munenori;KOHASHI Kyoko;MORI Yusaku;TERASAKI Michishige;KUSHIMA Hideki;NAGASHIMA Masaharu;SHINMURA Kyoko;TOMOYASU Masako;WATANABE Takuya;HIRANO Tsutomu, 75th Scientific Sessions American Diabetes Association, 07 Jun. 2015, Boston
  • SGLT-2阻害薬（Dapagliflozin/Ipragliflozin）は糖尿病マウス（STZ投与ApoE欠損、db/db）の動脈硬化進展を血糖依存性に抑制する, 寺﨑　道重;長嶋　理晴;広村　宗範;小橋　京子;九島　秀樹;森　雄作;平野　勉, 第58回日本糖尿病学会年次学術集会, 23 May 2015, 下関
  • 2型糖尿病患者におけるMDA-LDLと持続血糖モニタリング(CGM)で得られる血糖変動指標および各種検査所見との関係, 九島　秀樹;小原　信;林　俊行;樋口　明子;前木　展子;富田　高臣;山本　咲;広村　宗範;小橋　京子;森　雄作;原　賀子;長村　杏奈;髙橋　育克;福井　智康;平野　勉, 第58回日本糖尿病学会年次学術集会, 23 May 2015, 下関
  • 2型糖尿病患者における血中脂肪酸とsmall dense LDLとの関係, 林　俊行;前木　展子;富田　高臣;山本　咲;九島　秀樹;広村　宗範;小橋　京子;新村　京子;樋口　明子;友安　雅子;原　賀子;李　相翔;小原　信;長嶋　理晴;森　雄作;長村　杏奈;山本　剛史;髙橋　育克;福井　智康;平野　勉, 第58回日本糖尿病学会年次学術集会, 22 May 2015, 下関
  • 世界糖尿病デーイベントにおける血糖・HbA1c・CAVI・体組成測定の試み, 田森　里佳;林　弘将;池田　義晃;出原　祐美;栗原　彩加;川島　渉;土屋　亜由美;中村　明弘;小出　麻未;中田　美江;前木　展子;九島　秀樹;富田　高臣;山本　咲;広村　宗範;樋口　明子;小橋　京子;友安　雅子;原　賀子;森　雄作;長村　杏奈;山本　剛史;林　俊行;髙橋　育克;福井　智康;平野　勉, 第58回日本糖尿病学会年次学術集会, 21 May 2015, 下関
  • DPPⅣ阻害薬はマウスモデルにおいてインクレチン非依存性にアンギオテンシンⅡ誘発性心肥大を抑制する, 広村　宗範;小橋　京子;森　雄作;寺﨑　道重;九島　秀樹;長嶋　理晴;平野　勉, 第58回日本糖尿病学会年次学術集会, 21 May 2015, 下関
  • Dapagliflozinの経口投与はSTZ投与糖尿病ApoE欠損マウスの動脈硬化進展を抑制する, 寺﨑　道重;長嶋　理晴;広村　宗範;小橋　京子;九島　秀樹;森　雄作;平野　勉, 第88回日本内分泌学会学術総会, 23 Apr. 2015, 東京
  • 2型糖尿病における食後non HDL-Cの変動, 森　雄作;山本　剛史;長村　杏奈;平野　勉, 第44回日本動脈硬化学会総会・学術集会, 19 Jul. 2012, 福岡
  • コレステロール吸収マーカーは他の血清脂質と独立した腎障害の危険因子となる, 森　雄作;平野　勉, 第23回腎と脂質研究会, 08 Oct. 2011, 東京
  • Ezetimibe prevents kidney damage in 5/6 nephrectomized rats fed high-cholesterol by suppression of cholesterol absorption, MORI Yusaku;HIRANO Tsutomu, 71st Scientific Sessions 2011 American Diabetes Association, 24 Jun. 2011, San Diego
  • コレステロール吸収マーカーは他の血清脂質と独立した腎障害の危険因子となる　5/6腎臓摘出ラットにおける検討, 森　雄作;平野　勉, 第54回日本糖尿病学会年次学術集会, 21 May 2011, 札幌
  • 2型糖尿病患者においてエゼチミブはsmall dense LDLコレステロールを優先的に低下させる, 原　賀子;林　俊行;森　雄作;福井　智康;平野　勉, 第54回日本糖尿病学会年次学術集会, 21 May 2011, 札幌
  • テストミールA食を用いた食後高脂血症の簡便な評価方法 2型糖尿病患者における検討, 森　雄作;山本　剛史;徳野　杏奈;平野　勉, 第53回日本糖尿病学会年次学術集会, 27 May 2010, 岡山

MISC

  • インクレチン関連薬が拓く動脈硬化抑制作用の明日への希望, 森　雄作;平野　勉, Medicament News, (2200):6 - 7, Jul. 2015, ライフ・サイエンス

Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.